PDS Biotechnology Corporation (NASDAQ: PDSB) shares surged 38.18% during regular trading hours on September 8, 2026, climbing from $0.22 to $0.31. The move was triggered by a financing announcement made public at 12:30 PM ET that day.
What Drove the Move
The primary catalyst is a financing deal worth up to $22.55 million, led by Dr. Patrick Soon-Shiong, founder of NantWorks. Dr. Soon-Shiong is a prominent biotech investor and entrepreneur, which drew attention from traders focused on clinical-stage healthcare names.
PDS Biotechnology is a clinical-stage biopharmaceutical company developing immunotherapies for cancer. Its lead candidate, PDS0101, is in a Phase II trial targeting HPV-associated head and neck cancer and cervical cancer. The company is also advancing PDS01ADC in colorectal cancer and prostate cancer programs.
The financing provides runway for ongoing clinical operations, a key concern for small-cap biotechs with limited revenue.
Post-Market Activity
In the post-market session following the regular-hours surge, PDSB added another 1.35% to $0.3081, with volume of approximately 12 million shares. This modest after-hours gain suggests the initial reaction was largely absorbed during regular trading, with limited additional news pushing the stock further.
Key Facts to Know
- PDS Biotechnology has 24 employees and a market cap around $17.3 million
- Average daily volume is roughly 4.3 million shares, meaning today's volume of 491 million shares was roughly 114 times the norm
- Short interest stands at 1.89 million shares with 1.0 days to cover, indicating elevated short-squeeze potential
What Comes Next
The company will need to execute on its clinical milestones with the new capital. PDS0101 remains the most advanced program, with Phase II trials ongoing and potential Phase III plans in development. Traders will watch for further announcements regarding trial enrollment or regulatory milestones that could sustain momentum beyond this financing news.